CoChat

Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms

Quinn, J E, Brown, L G, Zhang, J, Keller, E T, Vessella, R L, Corey, E · 2005 · Prostate Cancer and Prostatic Diseases

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Zoledronic acid (ZA) has been shown to inhibit prostate tumor growth in vitro and have beneficial effects in patients with advanced prostate cancer (CaP). The aim of this study was to determine whether ZA exhibits direct anti-tumor effects on CaP cells in vivo. To distinguish the effects of inhibition of osteolysis and direct anti-tumor activity of ZA in vivo, we compared the results of treatment with ZA and osteoprotegerin (Fc-OPG), which inhibits osteolysis, but without significant direct anti-tumor effects. In vitro Fc-OPG had no significant effects on C4-2 proliferation, whereas ZA decreased proliferation. However, both agents decreased tumor growth in bone. Moreover, both increased bone volume and prevented the overall decreases in BMD associated with growth of C4-2 cells in bone. Our study provides novel and significant observations that the in vivo effects of ZA are consistent with indirect effects mediated by osteoclasts.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.pcan.4500815

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

Metadata

Authors
Quinn, J. E., Brown, L. G., Zhang, J., Keller, E. T., Vessella, R. L., & Corey, E.
Affiliations
  • University of Washington (US)
  • University of Michigan (US)
Corresponding author
Corey, E
Venue
Prostate Cancer and Prostatic Diseases
Published
2005-07-05
Volume
8
Issue
3
Pages
253-259
ISSN
  • 1365-7852 (ISSN-L)
  • 1476-5608
OpenAlex
W2027402812
Cited by
29
References
26
Citations by year
2018: 1 · 2015: 1 · 2014: 1 · 2013: 3 · 2012: 3
FWCI
2.19
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Prostate Cancer and Prostatic Diseases (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Abbott Laboratories
  • Amgen
  • Novartis
  • National Institutes of Health
  • Novartis Pharma
  • National Cancer Institute (P01 CA85859-01A, P01CA085859)
  • DOD Prostate Cancer Research Program
Topics
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
zoledronic acid, prostate cancer, bone metastasis, osteolysis, osteoclasts, tumor cell proliferation, bone volume, bone mineral density, bisphosphonates
MeSH terms
Zoledronic Acid, Animals, Antibodies, Antineoplastic Agents, Bone Neoplasms, Densitometry, Diphosphonates, Glycoproteins, Humans, Imidazoles, Immunoglobulin Fc Fragments, Male, Neoplasm Metastasis, Osteoclasts, Osteolysis, Prostatic Neoplasms, Tibia, Time Factors, Bone Density, Mice, SCID, Apoptosis, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Cell Proliferation, Bone Density Conservation Agents, Mice, Osteoprotegerin, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.